Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,039.48 +6.51 (+0.63%)
Streaming Delayed Price Updated: 3:30 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Could This Potential Move Boost Eli Lilly's Prospects? ↗
The stock already looks unstoppable, and this move won't hurt its momentum. 
Via The Motley Fool
News headline image
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗
Via MarketBeat
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
S&P 500 Hovers at the Flatline: A Masterclass in Market Resilience or the Quiet Before a 2026 Storm?
As the sun sets on 2025, the S&P 500 is holding its breath. In a trading session characterized by thin holiday volume and a notable absence of institutional conviction, the benchmark index spent much... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk Stock Dropped on Monday ↗
The cost of Wegovy is about to decrease significantly in a populous overseas market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility
As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High? ↗
History is clear about what investors should do heading into the new year. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗
Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers. 
Via Chartmill
News headline image
Monday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era
In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change
News headline image
The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance
As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The Great Rebalancing: Investors Pivot Away from Big Tech as 2026 Looms
As the final trading days of 2025 wind down, a massive tactical shift is sweeping through Wall Street. Institutional fund managers and retail investors alike are aggressively rebalancing portfolios,... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
The Great Pivot: Navigating the Rollercoaster 2025 Market as the Final Bell Approaches
As the sun sets on December 29, 2025, the U.S. stock market stands at a historic crossroads, capping off a year defined by extreme volatility, political brinkmanship, and a definitive shift in monetary... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
S&P 500 Tests Resilience: Technical Pullback Follows Historic Record Highs as 2025 Draws to a Close
The S&P 500 (NYSE:SPY) entered the final week of 2025 in uncharted territory, having notched a series of historic closing records that culminated in a Christmas Eve milestone. However, as the calendar... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
Is this the start of a sustained run for the Danish drugmaker? 
Via The Motley Fool
News headline image
Eli Lilly & Co (NYSE:LLY) Stands Out as a Secure Dividend Growth Stock ↗
Eli Lilly (LLY) offers a secure, growing dividend supported by strong profitability and financial health, ideal for a dividend growth investment strategy. 
Via Chartmill
News headline image
Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai. 
Via Stocktwits
Topics Intellectual Property
News headline image
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now. 
Via The Motley Fool
News headline image
1 Stock Under $50 on Our Buy List and 2 We Find Risky
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Economy
News headline image
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Stocks to Invest $50,000 in Right Now ↗
If you're investing for the long run, there are a myriad of companies begging to be bought. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Here Are My Top 3 Growth Stocks to Buy Now ↗
These profitable businesses have plenty of room left to run. 
Via The Motley Fool
News headline image
Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.